These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 16387501)

  • 1. Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin.
    Bonneux IM; Bellemans J; Fabry G
    Knee; 2006 Mar; 13(2):118-21. PubMed ID: 16387501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
    Turpie AG
    Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
    ; Mehta SR; Yusuf S; Granger CB; Wallentin L; Peters RJ; Bassand JP; Budaj A; Joyner C; Chrolavicius S; Fox KA
    Am Heart J; 2005 Dec; 150(6):1107. PubMed ID: 16338245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
    Mehta SR; Granger CB; Eikelboom JW; Bassand JP; Wallentin L; Faxon DP; Peters RJ; Budaj A; Afzal R; Chrolavicius S; Fox KA; Yusuf S
    J Am Coll Cardiol; 2007 Oct; 50(18):1742-51. PubMed ID: 17964037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
    Turpie AG; Bauer KA; Davidson BL; Fisher WD; Gent M; Huo MH; Sinha U; Gretler DD;
    Thromb Haemost; 2009 Jan; 101(1):68-76. PubMed ID: 19132191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of fondaparinux versus enoxaparin after TKA in Japanese patients.
    Hosaka K; Saito S; Ishii T; Sumino T; Ryu K; Suzuki G; Suzuki T; Tokuhashi Y
    Orthopedics; 2013 Apr; 36(4):e428-33. PubMed ID: 23590781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboprophylaxis dosing: the relationship between timing of first administration, efficacy, and safety.
    Kwong LM; Muntz JE
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):16-20. PubMed ID: 12463579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
    Turpie AG; Eriksson BI; Bauer KA; Lassen MR
    Chest; 2003 Dec; 124(6 Suppl):371S-378S. PubMed ID: 14668420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
    Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
    Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study.
    Singelyn FJ; Verheyen CC; Piovella F; Van Aken HK; Rosencher N;
    Anesth Analg; 2007 Dec; 105(6):1540-7, table of contents. PubMed ID: 18042845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.
    Westrich GH; Bottner F; Windsor RE; Laskin RS; Haas SB; Sculco TP
    J Arthroplasty; 2006 Sep; 21(6 Suppl 2):139-43. PubMed ID: 16950076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design of venous thromboembolism prophylaxis trials: is enoxaparin more effective than fondaparinux?
    Lalourcey L
    Int J Clin Pract; 2003 May; 57(4):289-94. PubMed ID: 12800460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thromboprophylaxis and peripheral nerve blocks in patients undergoing joint arthroplasty.
    Chelly JE; Schilling D
    J Arthroplasty; 2008 Apr; 23(3):350-4. PubMed ID: 18358371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs low molecular weight heparin.
    Gelfer Y; Tavor H; Oron A; Peer A; Halperin N; Robinson D
    J Arthroplasty; 2006 Feb; 21(2):206-14. PubMed ID: 16520208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of the American College of Chest Physicians-1A protocol for lovenox in clinical outcomes for thromboembolic prophylaxis.
    Burnett RS; Clohisy JC; Wright RW; McDonald DJ; Shively RA; Givens SA; Barrack RL
    J Arthroplasty; 2007 Apr; 22(3):317-24. PubMed ID: 17400085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
    Sculpher MJ; Lozano-Ortega G; Sambrook J; Palmer S; Ormanidhi O; Bakhai A; Flather M; Steg PG; Mehta SR; Weintraub W
    Am Heart J; 2009 May; 157(5):845-52. PubMed ID: 19376310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of anticoagulation on the restoration of range of motion after total knee arthroplasty: enoxaparin versus aspirin.
    Keays AC; Mason M; Keays SL; Newcombe PA
    J Arthroplasty; 2003 Feb; 18(2):180-5. PubMed ID: 12629608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.